ClinicalTrials.gov
ClinicalTrials.gov Menu

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00760916
Recruitment Status : Withdrawn (Study stopped prior to subject enrollment.)
First Posted : September 26, 2008
Last Update Posted : January 30, 2013
Sponsor:
Information provided by:
United Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Actual Primary Completion Date : January 2009
  Actual Study Completion Date : January 2009